Haemonetics (HAE) Revenue (2009 - 2026)

Haemonetics has reported Revenue for 18 years, with the latest figure at $339.4 million in Q2 2026.

• On a quarterly basis, Revenue rose 5.6% year-over-year to $339.4 million in Q2 2026; TTM through Jun 2026 was $1.4 billion, a 0.44% change from a year earlier, with the FY2026 full-year figure at $1.3 billion, down 1.97% from the prior year.
• Revenue was $339.4 million for Q2 2026 at Haemonetics, down from $346.4 million in the prior quarter.
• The five-year high for Revenue was $348.5 million in Q4 2024, with the low at $259.8 million in Q1 2022.
• Average Revenue over 5 years is $317.7 million, with a median of $327.3 million recorded in 2025.
• The sharpest annual moves came in 2022 and 2025: Revenue gained 24.01% in 2022, then dropped 5.27% in 2025.
• Over 5 years, Revenue stood at $305.3 million in 2022, then grew by 10.14% to $336.2 million in 2023, then gained by 3.66% to $348.5 million in 2024, then retreated by 2.75% to $339.0 million in 2025, then rose by 0.12% to $339.4 million in 2026.
• The last three Revenue figures came in at $339.4 million (Q2 2026), $346.4 million (Q1 2026), and $339.0 million (Q4 2025), per Business Quant data.